The aim of this study was to evaluate the quality of life (QoL) of patients treated with a topical anti-glaucoma drug in usual practice. METHODS: A mailing was sent to 20,000 homes belonging to the Sofres panel (representative to the French population according to the quota method) asking whether one member of the family was treated for glaucoma. A computer-assisted telephone interviewing system was used to confirm self-reported glaucoma treatment, to describe the disease and its treatment, as well as medical item consumption. Vision-related QoL was assessed with the NEI-VFQ-25 and local tolerance and its QoL consequences with the COMTOL. RESULTS: 13,352 homes (66.7%) or 32,685 people answered the mail. Five hundred eighty one people declared they had glaucoma, leading to glaucoma and ocular hypertension treatment prevalence of 1.8%, increasing with age. From them, 204 people were selected at random. Their NEI-VFQ-25 global score was high (80.2) showing an overall good QoL. Two scores showed some deterioration: general health (48.8) and driving (53.9). Ninetyone (44.6%) patients changed their treatment at least once: 55% due to poor efficacy and 35% for adverse events. Being queried with the COMTOL, 62% of the patients cited at least one local adverse event: 25% had burning, 21% blurred vision, 20% tearing and 16% itching among others. Sixty percent of the patients visited their ophthalmologist twice a year and 90% of the patients declared they were satisfied or very satisfied with their treatment. CONCLUSION: Based on a French representative sample, the overall satisfaction of patients treated with antiglaucoma drugs is high, although half of them have changed their treatment at least once and the majority of them declared an adverse event when queried. Eye related QoL was not affected in the majority of the patients.
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QUALITY OF LIFE OF FRENCH PATIENTS TREATED FOR PRIMARY OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION
Auzanneau N 1 , Touboul C 1 , Berdeaux G 2 1 Taylor Nelson Sofres, Montrouge, France; 2 Alcon, Rueil-Malmaison, France OBJECTIVE: The aim of this study was to evaluate the quality of life (QoL) of patients treated with a topical anti-glaucoma drug in usual practice. METHODS: A mailing was sent to 20,000 homes belonging to the Sofres panel (representative to the French population according to the quota method) asking whether one member of the family was treated for glaucoma. A computer-assisted telephone interviewing system was used to confirm self-reported glaucoma treatment, to describe the disease and its treatment, as well as medical item consumption. Vision-related QoL was assessed with the NEI-VFQ-25 and local tolerance and its QoL consequences with the COMTOL. RESULTS: 13,352 homes (66.7%) or 32,685 people answered the mail. Five hundred eighty one people declared they had glaucoma, leading to glaucoma and ocular hypertension treatment prevalence of 1.8%, increasing with age. From them, 204 people were selected at random. Their NEI-VFQ-25 global score was high (80.2) showing an overall good QoL. Two scores showed some deterioration: general health (48.8) and driving (53.9). Ninetyone (44.6%) patients changed their treatment at least once: 55% due to poor efficacy and 35% for adverse events. Being queried with the COMTOL, 62% of the patients cited at least one local adverse event: 25% had burning, 21% blurred vision, 20% tearing and 16% itching among others. Sixty percent of the patients visited their ophthalmologist twice a year and 90% of the patients declared they were satisfied or very satisfied with their treatment. CONCLUSION: Based on a French representative sample, the overall satisfaction of patients treated with antiglaucoma drugs is high, although half of them have changed their treatment at least once and the majority of them declared an adverse event when queried. Eye related QoL was not affected in the majority of the patients. Atopic dermatitis (AD) is a common chronic dermatological disease affecting mainly young children. According to epidemiological studies, its prevalence has increased notably over the last two decades. OBJECTIVE: To assess the economic burden of AD in Germany.
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THE SOCIETAL COST OF ATOPIC DERMATITIS IN GERMANY
METHODS:
A prevalence approach was adopted to evaluate the societal cost of AD comprising direct medical costs, indirect costs, and out-of-pocket expenses. Not included in this evaluation is the impact of AD on the patient and the family in terms of an impaired quality of life. Data were collected from various sources: health statistics; labor statistics; literature; surveys, and an expert panel of six dermatology specialists. All costs were adjusted to the year 1999. In order to explore the findings in light of data variations, sensitivity analyses were performed. RESULTS: Based on an estimated base case population of 2.45 million people suffering from AD, total annual societal costs amount to DEM 1.32 billion (EUR 678 million). Of these overall costs, DEM 636 million (48%) are attributable to direct costs, DEM 428 million (32%) to productivity losses (including time expenditures of parents caring for their sick children), and DEM 257 million (20%) to out-of-pocket expenses. The most important individual cost contributor is outpatient physician care (28%), followed by time expenditure of parents (20%), and out-of-pocket expenses (19%). Drug treatment accounts for less than 10% of the overall costs. The average per-patient societal cost of AD is around DEM 540 per year. Sensitivity analysis showed a maximum variation in yearly costs ranging between DEM 1.08 billion and DEM 1.61 billion when both prevalence and utilization estimates are varied. CONCLUSIONS: The chronic nature of AD coupled with its high frequency represents a significant economic burden to society in Germany. Based on these findings it can be concluded that AD cannot be regarded as a minor illness.
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IS NON-CONTACT NORMOTHERMIC WOUND THERAPY COST-EFFECTIVE FOR THE TREATMENT OF STAGE 3 AND 4 PRESSURE ULCERS?
Macario A 1 , Dexter F 2 1 Stanford University, Stanford, CA, USA; 2 Univeristy of Iowa, Iowa City, IA, USA OBJECTIVES: Chronic pressure ulcers are a significant health problem for patients in long-term-care facilities. The value of restoring quality of life following a pressure ulcer injury has attracted new treatments. Non-contact normothermic wound therapy (NNWT) (Warm-Up therapy) is a semi-occlusive, moisture retentive wound cover ($240/wound cover/ 2 days) that is warmed to 38ЊC to promote healing. The goal of this study was to examine the incremental cost-effectiveness of NNWT relative to the current standard of care for treatment of stage III and IV pressure ulcers. METHODS: A Markov cost-effectiveness, computer-simulation model with hypothetical patients was created. The base case involved a 72-year-old man, living in a nursing home, with a stage III ischial pressure ulcer. Standard care was assumed to include moisture retentive dressings, a pressure reducing surface, repositioning, and debridement. RESULTS: Our modeling predicted the total expected cost of standard care treatment for a stage 3 pressure ulcer to be $20,874. Randomized clinical trials have found that NNWT (n ϭ 72 patients) decreases the surface area of stage 3-4 pressure ulcers by 2.5 fold (SD 59%) over standard care (n ϭ 59 patients). The eight-week healing rates for stage 3 ulcers are 71% with NNWT and 54% for standard care. At these healing rates, our modeling for stage 3 pressure ulcers found that for a 40 month time frame NNWT saves $6,630 (SE $98) and increases QALYs by 0.10 (SE 0.0005) life years compared to standard care. For stage 4 pressure ulcers, NNWT saves $15, 216(SE $186) and increases QALYs by 0.14 (SE 0.001). CONCLUSIONS: NNWT in patients with stage 3 and 4 pressure ulcer is an economically attractive intervention. Additional well-controlled clinical trials are necessary to further define the role of NNWT in the care of chronic wounds. 
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PSORIASIS AND EVERYDAY LIFE: FIRST RESULTS
METHOD:
Four thousand five hundred anonymous questionnaires were sent, via a Patient Support Group acting against Psoriasis (Association Pour la Lutte Contre le Psoriasis, APLCP). The questionnaires consisted of two scales: the Psoriasis Disability Index and 10 questions concerning the treatment and evolution of psoriasis. RESULTS: Twenty-five days after the mailing, 2014 questionnaires (44%) were received. An analysis of the first questionnaire was conducted. The respondents were 54% women, average age was 50 years, and for men, 53 years. The average age at diagnosis for men was 30 years, and for women, 25 years. Women are significantly more adversely affected than men in their everyday activities. Men are significantly more adversely affected than women at work. No difference was observed between men's and women's global scores. Psoriasis seems to incapacitate 16 to 55 year olds in their social relations, leisure activities and how well they keep their house more than it does older subjects. Long-standing psoriasis does not seem to be more of a handicap to people than more recent psoriasis. The global score is similar. However, a clear trend is observed between the age at the moment of diagnosis and the level of incapacity (p ϭ .0176). The younger the indi-vidual in which psoriasis is diagnosed, the higher the level of incapacity. This is particularly marked in terms of the everyday and leisure scores. CONCLUSION: These results highlight the value of appropriate and relevant psychological and medical environment for children suffering from psoriasis.
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THE WILLINGNESS TO PAY FOR PHARMACOTHERAPY OF ATOPIC DERMATITIS
Ikeda S 1 , Tamura M 2 , Yamaki S 3 , Nakagawa H 4 1 Keio University, Tokyo, Japan; 2 International University of Health and Welfare, Otawara, Japan; 3 University of Tokyo, Tokyo, Japan; 4 Jichi Medical School, Tochigi, Japan OBJECTIVE: For patients with atopic dermatitis, longterm treatment is usually unavoidable and various limitations are caused in their daily life. Therefore, the influence on the patient of new, innovative pharmacotherapy for atopic dermatitis is thought to be extremely large from an economic viewpoint. In this study, we attempted to measure willingness to pay (WTP) for the newly developed therapeutic agent, "tacrolimus". METHODS: 1,000 men and women, 20-59 years old and living in the Tokyo metropolitan area, were selected by random sampling for the interview survey. The bidding game method and the take-it-or-leave-it approaches were adopted. Eight patterns of health-care costs for one month (from 625 to 80,000 yen) were allocated to each respondent at random to avoid "starting point bias". We estimated the demand curve, assuming that the log transformation of WTP will be distributed as a logistic function. RESULTS: A total of 431 interviews (43.1% of the candidates) were completed. More than half responded as "yes" to the price of 10,000 yen or less. The demand curve was estimated to be: P(x)ϭ1/(1 ϩ exp(Ϫ5.5239 ϩ 0.5906 ln(x))). The median of WTP was 11,537 yen (95% CI: 8,967-14,845). CONCLUSION: It can be interpreted that the average amount people are willing to pay for tacrolimus pharmacotherapy is 11,500 yen a month. This information is considered to be beneficial for clinical decision-making as well as policy decision-making such as price setting and reimbursement decisions.
